Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP
Chokri Ben Lamine, Hematologist at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Persistent/chronic immune thrombocytopenia (ITP): treatment toolbox.
TPO receptor agonists – romiplostim, eltrombopag, avatrombopag: increase platelet production.
Fostamatinib – SYK inhibitor: reduces immune-mediated platelet destruction.
Rilzabrutinib – oral BTK inhibitor; FDA-approved for adults with persistent/chronic ITP after insufficient response to prior treatment.
Rituximab – anti-CD20; commonly used off-label.
Corticosteroids plus/minus IVIG – short-term rescue when a rapid platelet rise is needed; avoid prolonged steroid exposure.
Splenectomy – an option for selected patients seeking durable response.
Individualize by bleeding, comorbidities, prior response, treatment burden and patient preference.
Aim for a safe platelet count-not normalization.
Approval and availability vary by country.
Sources: ASH ITP guidelines | FDA rilzabrutinib label.”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Oct 23, 2026, 13:51Julia Barr: Blood Donation, Banter, and a Tunnock’s Teacake
-
Oct 23, 2026, 13:45Marta Velia Antonini: EuroELSO Webinar to Highlight New Evidence on ECMO Anticoagulation
-
Oct 23, 2026, 13:16Mary Cushman: Antiphospholipid Antibodies and Their Association with Ischemic Stroke
-
Oct 23, 2026, 13:07Cristina Figueroa Villalba: AABB 2026 Highlights in Transfusion Medicine and Cell Therapy
-
Oct 23, 2026, 13:02Jesus Ardila Novoa: New Therapies for ITP
-
Oct 23, 2026, 12:49Wolfgang Miesbach: Factor XI Inhibition and the Future of Precision Anticoagulation
-
Oct 23, 2026, 12:47Pier Maria Fornasari: Expanding Access to Curative Treatment for Aplastic Anaemia
-
Oct 23, 2026, 12:36Filipe Gonçalves: Scientific Progress Depends on More Than Individual Expertise
-
Oct 23, 2026, 10:40Janet Tankersley: Joint and Cardiometabolic Health in Children with Severe Haemophilia A